Disclosure Policies
Basic Policy
Otsuka Holdings Co., Ltd. (hereinafter referred to as “the company”) is committed to providing timely and appropriate information to all stakeholders - including employees, customers, business partners, society, and shareholders - based on the fundamental principles of transparency, fairness, and continuity.
Scope of Disclosure
The company appropriately discloses financial and non-financial information of the Otsuka group* (hereinafter referred to as “the Group”) in accordance with the Financial Instruments and Exchange Act, the rules of the Tokyo Stock Exchange (TSE), and its internal administrative guidelines. In addition, the company proactively discloses voluntary information not required by laws or regulations with the aim of building trust with its stakeholders.
*The Otsuka Group, which is comprised of Otsuka Holdings Co., Ltd. and its subsidiaries and affiliated companies.
1. Methods of Disclosure
Material information subject to the TSE's Timely Disclosure Rules is disclosed by registering such information with the Timely Disclosure network (TDnet) operated by the TSE, after providing a prior explanation to the TSE. After registration with TDnet, the company will promptly post the same information on its website without delay. Information that does not fall under the scope of timely disclosure will also be disclosed, as appropriate to its content, through suitable methods such as publication on the company’s website and the distribution of news releases.
2. Timely Disclosure System
The company’s timely disclosure process is reviewed by the Timely Disclosure Review Committee, which is chaired by the manager in charge of insider trading control (Director&Board Member in charge of Administration) and composed of members from relevant departments, including the Investor Relations Department and the Public Relations Department. Material information collected from the company and its group companies is promptly reviewed to determine whether disclosure is required. If disclosure is deemed necessary, the relevant materials are prepared. Upon approval by the manager in charge of insider trading control, the department responsible for timely disclosure will promptly disclose the information through TDnet.
3. Items Related to Forward-Looking Statements
Items posted on the company’s website that are not related to actual past or current facts are forward-looking statements, which are made based on judgments and assumptions using the information available at the time the respective statement is made. Actual results may therefore materially differ as a result of various risks, uncertainties, and economic circumstances.
4. Quiet Period
To ensure fairness and prevent leaks of information regarding financial results, the company maintains a “Quiet Period” starting on the day following the end of each quarter up to the day of the announcement of the respective quarterly results. During this period, the company refrains from answering any questions and making any comments related to financial information. However, if a significant change to the company’s previously announced financial results forecast occurs during the quiet period, that information will be released in accordance with the TSE's Timely Disclosure Rules. During the quiet period, the company still responds to questions related to previously released information and requests for interviews limited to Otsuka's management plans and topics other than financial results information.
5. Prevention of Insider Trading
The company has established the Insider Trading Management Rules, which set forth the management of material information of the company, its subsidiaries and other companies, as well as general conditions regarding the trading of shares and other securities. The company strives to prevent insider trading by strictly managing material information and related parties and by conducting regular training on insider trading regulations.
6. About Product and Technical Information
This website contains product information on pharmaceuticals and medical devices, including those under development, as well as functional beverages, functional foods, nutritional supplements and related research results and technical information concerning ongoing research themes. This information is intended to provide fair and transparent disclosure to stakeholders and is not intended for advertising, promotional, or medical advisory purposes.
Established in December 2010
Revised in January 2022
Revised in April 2026